Comparison · NCT00852540-cb2ecdfe
Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants Who Achieved Microbiological Response (MR) at Follow-up (FU) Who Had a Baseline Pathogen (BP)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants Who Achieved Microbiological Response (MR) at Follow-up (FU) Who Had a Baseline Pathogen (BP). Trial comparisons, record NCT00852540-cb2ecdfe. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00852540-cb2ecdfe
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.565 | 0.491 | 0.636 | wilson | |
| Risk in group 2 | 0.833 | 0.735 | 0.9 | wilson | |
| Risk difference, group 1 minus group 2 | -0.268 | -0.368 | -0.148 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.678 | 0.576 | 0.798 | log | |
| Odds ratio, group 1 over group 2 | 0.26 | 0.134 | 0.505 | log | |
| Number needed to treat, for one fewer participant with the outcome on Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo than on Linezolid Plus Placebo Ointment | 3.73 | 2.72 | 6.78 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo | Retapamulin ointment was administered topically twice daily (BID) for 5 days. The ointment formulation was to be applied to the infected lesion(s) at a dose of approximately 10 milligrams (mg) per centimeter squared (cm\^2). Placebo was to be dosed, depending on participant age, either BID or three times a day (TID) for 10 days. Placebo oral suspension and oral tablet were formulated to appear identical to the linezolid formulations. Adolescent and adult participants (\>=12 years of age) were dosed BID with 600 mg placebo tablets, pediatric participants 5 to 11 years of age were dosed with oral suspension at 0.5 milliliters (ml)/kilogram (kg) BID, and pediatric participants less than 5 years of age were dosed with oral suspension at 0.5 ml/kg TID. | 100 | 177 | OG000 |
| Group 2 | Linezolid Plus Placebo Ointment | Linezolid was to be dosed, depending on participant age, either BID or TID for 10 days. Adolescent and adult participants (\>=12 years of age) were dosed BID with 600 mg tablets for 10 days. Pediatric participants who were 5-11 years of age were dosed with a 100 mg/5 ml oral suspension at a dose of 10 mg/kg BID for 10 days. Pediatric participants who were \<5 years of age were dosed with a 100 mg/5 ml oral suspension at a dose of 10 mg/kg TID for 10 days. Placebo ointment was administered topically BID for 5 days. | 65 | 78 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Achieved Microbiological Response (MR) at Follow-up (FU) Who Had a Baseline Pathogen (BP)
- Description
MR was defined as microbiological success if, (1) for participants (par.) whose clinical outcome at end of therapy (EOT) was clinical success (CS)/improvement, the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and absent at FU, or the BP was eradicated/presumed to be eradicated at EOT, or the BP was present at EOT and par. was a CS such that no culture was obtained due to lack of culturable material secondary to adequate clinical response; or (2) a pathogen not previously identified at baseline was isolated at FU in a par. identified at FU as a CS.
- Time frame
- 7-9 days post-therapy; Day 12-14 for retapamulin and Day 17-19 for linezolid
- Population
- Intent-to-Treat Bacteriology (ITTB) Population: all randomized participants who took at least one dose of study medication and who had a pathogen isolated at baseline.
Source ClinicalTrials.gov
Trial
- Title
- Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
- NCT number
- NCT00852540
- Phases
- PHASE3
- Conditions
- Skin Infections, Bacterial
- Interventions
- Retpamulin Ointment, 1%, Linezolid
- Lead sponsor
- Stiefel, a GSK Company
- Results first posted
- 2011-08-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00852540?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00852540-cb2ecdfe